Table 5.
Microvascular complications and other treatments.
| Variable | Baseline | Week 52 | |||||
|---|---|---|---|---|---|---|---|
| Dulaglutide (n = 16) | Glargine (n = 9) | p | Dulaglutide (n = 16) | Glargine (n = 9) | p | ||
| Diabetic nephropathy, n (%) | 3 | 2 | 0.835 | 3 | 3 | 0.412 | |
| Other comorbidities, n (%) | |||||||
| Hyperlipidemia | 5 | 4 | 0.509 | 6 | 4 | 0.734 | |
| Hypertension | 11 | 5 | 0.509 | 11 | 5 | 0.509 | |
| Other treatments, n (%) | |||||||
| CCB | 4 | 3 | 0.656 | 4 | 3 | 0.656 | |
| ACEI/ARB | 5 | 2 | 0.629 | 5 | 2 | 0.629 | |
| Beta-blockers | 2 | 0 | 0.260 | 2 | 0 | 0.260 | |
| Statins | 3 | 2 | 0.835 | 4 | 2 | 0.876 | |
CCB: calcium channel blockers; ACEI/ARB: angiotensin-converting enzyme inhibitor and/or angiotensin II receptor blocker.